Please login to the form below

Not currently logged in
Email:
Password:

German partners find diabetes biomarker

Helmholtz Zentrum München and Boehringer Ingelheim have identified a biomarker for diabetes-relevant protein

Helmholtz Zentrum München and Boehringer Ingelheim have jointly identified a biomarker for diabetes-relevant protein.

The indicator will enable the pre-clinical testing of FABP4 inhibitors, therefore facilitating the selection of potentially effective substances. Studies on human subjects and mouse models show that the FABP4 protein could be a potential target protein for new drugs to treat diabetes mellitus and atherosclerosis.

The biomarker was found through the use of lipidomics and metabolomics. Scientists at the Helmholtz Zentrum München were the first to use the modern lipidomics technologies to successfully identify such functionally relevant biomarkers for FABP4.

Boehringer Ingelheim provided the necessary biological and indication-specific knowledge; the Helmholtz Zentrum München contributed expertise in metabolomics and bioinformatics.

The development of the biomarker for FABP4 was the pilot project for the collaborative research venture to identify functional biomarkers.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

blood
‘How is your day?’
The initiative that shows how plasma protein therapies improve lives...
women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....

Infographics